Navigation Links
Tiens Biotech Group (USA) Reports 2010 Results
Date:3/31/2011

048CASH FLOWS FROM INVESTING ACTIVITIES:Cash outflow arising from disposal of a subsidiary-(23,975,473)Collections from loans to local government -105,229Construction deposits(11,248,302)(2,664,741)Contractor deposits19,30619,734Addition to construction in progress(54,487,459)(42,734,161)Equipment deposits(6,102,039)(11,782,984)Proceeds from sales of properties73,65029,131Purchase of equipment and automobiles(1,441,906)(2,009,536)Net cash used in investing activities(73,186,750)(83,012,801)CASH FLOWS FROM FINANCING ACTIVITIES:Loan from (repayment to) related parties-(3,946,860)Proceed from short term debt2,958,800-Proceeds from long term debt18,048,680-Net cash provided by (used in) financing activities21,007,480(3,946,860)EFFECT OF EXCHANGE RATE CHANGES ON CASH128,87882,430INCREASE (DECREASE) IN CASH8,307,194(43,006,183)CASH, beginning of period1,848,32844,854,511CASH, end of period

$

10,155,522

$

1,848,328Supplemental disclosures of cash flow informationCash paid during the period for:Interest

$

217,154

$

105,817Income taxes

$

1,489,417

$

3,287,531The accompanying notes are an integral part of this statement.TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES REVENUE BY REGIONTwelve months endedDecember 31,20102009

ChangeChina  

$24,894,472

$27,241,333 - 8.6%International

$
,450,248

$
34,734,736-52.6%Total

$41,344,720

$61,976,069  -33.3%CONTACT:Investor Relations

Debra BerlinerTiens Biotech Group (USA), Inc.

G. S. Schwartz & Co.Tel:   +86-22-8213-7335

Tel:  212-725-4500Fax:  +86-22-8213-7914

Fax: 212-725-9188Email: investor@tiens-bio.com

Email: dberliner@schwartz.com http://www.tiens-bio.com
'/>"/>

SOURCE Tiens Biotech Group (USA), Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
2. Tiens Biotech Group (USA) Reports First Quarter Results
3. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
4. Tiens Biotech Group (USA) Reports First Quarter Results
5. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
6. Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results
7. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
8. Yongye Biotechnology International Retains CCG Investor Relations
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
11. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... in part) in, into or from any jurisdiction where to ... of such jurisdiction.  Shire plc ("Shire" or the ... Bloomberg article this afternoon.  Shire confirms it has held a ... being made by Shire without the prior agreement or approval ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... DCGN ) announced that on February 2, 2009, it ... "Panel") stating that the Panel,will transfer the listing of ... Nasdaq Capital Market, effective at the open of the ... Market, which is,one of the three market tier designations ...
... UPI ),a medical device company that develops, manufactures ... reported financial,results for the third quarter of fiscal 2009 ... quarter of fiscal 2009 were $3.4 million versus $3.7,million ... "As we discussed in conjunction with the ...
... Feb. 3 Genomic Health,Inc. (Nasdaq: GHDX ) ... and year ended December 31, 2008. , ... to $31.2 million,compared with $19.3 million in the fourth quarter ... assay was $30.9 million in the fourth,quarter of 2008, an ...
Cached Biology Technology:deCODE Announces Transfer of the Listing of its Common Stock from Nasdaq Global Market to Nasdaq Capital Market 2deCODE Announces Transfer of the Listing of its Common Stock from Nasdaq Global Market to Nasdaq Capital Market 3Uroplasty Reports Third Quarter Fiscal 2009 Results 2Uroplasty Reports Third Quarter Fiscal 2009 Results 3Uroplasty Reports Third Quarter Fiscal 2009 Results 4Uroplasty Reports Third Quarter Fiscal 2009 Results 5Uroplasty Reports Third Quarter Fiscal 2009 Results 6Uroplasty Reports Third Quarter Fiscal 2009 Results 7Uroplasty Reports Third Quarter Fiscal 2009 Results 8Uroplasty Reports Third Quarter Fiscal 2009 Results 9Uroplasty Reports Third Quarter Fiscal 2009 Results 10Uroplasty Reports Third Quarter Fiscal 2009 Results 11Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 2Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 3Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 4Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 5Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 6Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 7Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 8Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 9
(Date:7/11/2014)... in German . ... uses the refraction of X-rays through a specimen instead ... this method are often of much higher quality than ... of Prof. Franz Pfeiffer are particularly interested in developing ... including X-ray phase-contrast imaging. One main goal is to ...
(Date:7/11/2014)... July 3, 2014, Shenzhen, China Researchers from Salk ... for the first time evaluated the safety and ... and successfully developed a new method, TALEN-HDAdV, which ... pluripotent stem cell (hiPSC). This study published online ... important theoretical foundation for stem cell-based gene therapy. ...
(Date:7/11/2014)... July 11, 2014 Researchers have pioneered ... images. The new technology, called Virtual Finger, allows ... structures like neurons and synapses using the flat ... technology makes 3D imaging studies orders of magnitude ... an unprecedented level across many areas of experimental ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... Island of New Zealand is marked at approximately 38 S ... line". This region forms the southern distributional limit of many ... number of endemic plants are found there. Ecologists have recently ... the "kauri line". Wetlands serve vital ecological functions by ...
... and from Berkeley have used metal complexes to modify ... Chemical Society , they report for the first time ... "With this work, we have laid the molecular foundation ... Stoll from the Faculty of Chemistry and Biochemistry at ...
... MAResearchers from Brigham and Women,s Hospital (BWH) have made a ... The team, led by Thomas S. Kupper, MD, chair of ... that high expression of a cell-signaling molecule, known as interleukin-9, ... findings will be published online in the July 8, 2012 ...
Cached Biology News:A new species of wirerush from the wetlands in northern New Zealand 2A new avenue to better medicines: Metal-peptide complexes 2Researchers discover molecule in immune system that could help treat dangerous skin cancer 2